Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 254 entries
View as:

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00951015 Org: User:
Start: 07/30/09 End: 12/22/16 Due: 12/22/17

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Phase: N/A Priority: Normal
NCT ID: NCT01467518 Org: User:
Start: 12/31/11 End: 02/29/12 Due: 02/28/13

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04827134 Org: User:
Start: 05/07/21 End: 07/23/21 Due: 07/23/22

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT06039579 Org: User:
Start: 10/25/23 End: 06/24/24 Due: 06/24/25

Study on Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT02234882 Org: User:
Start: 09/05/14 End: 10/31/14 Due: 10/31/15

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05291520 Org: User:
Start: 02/23/22 End: 04/10/23 Due: 04/10/24

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05163522 Org: User:
Start: 12/13/21 End: 06/21/23 Due: 06/21/24

Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)

Phase: N/A Priority: Normal
NCT ID: NCT03816696 Org: User:
Start: 01/23/19 End: 04/10/19 Due: 04/10/20

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

Phase: N/A Priority: Normal
NCT ID: NCT05674656 Org: User:
Start: 07/06/23 End: 05/03/28 Due: 05/03/29

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05979311 Org: User:
Start: 02/09/24 End: 02/23/27 Due: 02/23/28

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01327547 Org: User:
Start: 05/18/11 End: 03/24/15 Due: 03/24/16

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01449929 Org: User:
Start: 10/31/11 End: 12/26/16 Due: 12/26/17

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Phase: N/A Priority: Normal
NCT ID: NCT00665561 Org: User:
Start: 03/31/08 End: 02/14/19 Due: 02/14/20

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Phase: N/A Priority: Normal
NCT ID: NCT00950859 Org: User:
Start: 08/31/09 End: 01/31/15 Due: 01/31/16

A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254

Phase: N/A Priority: Normal
NCT ID: NCT03575962 Org: User:
Start: 06/18/18 End: 08/06/18 Due: 08/06/19

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03441984 Org: User:
Start: 02/26/18 End: 04/28/18 Due: 04/28/19

GSK1349572 Relative Bioavailability Study

Phase: N/A Priority: Normal
NCT ID: NCT01098513 Org: User:
Start: 04/30/10 End: 07/31/10 Due: 07/31/11

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02576119 Org: User:
Start: 10/19/15 End: 10/14/16 Due: 10/14/17

Maraviroc Compassionate Use

Phase: N/A Priority: Normal
NCT ID: NCT00719823 Org: User:
Start: 08/31/08 End: 05/31/10 Due: 05/31/11

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Phase: N/A Priority: Normal
NCT ID: NCT01077557 Org: User:
Start: 11/30/06 End: 11/30/11 Due: 11/30/12

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01068925 Org: User:
Start: 02/15/10 End: 04/05/10 Due: 04/05/11

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

Phase: N/A Priority: Normal
NCT ID: NCT03639311 Org: User:
Start: 09/24/18 End: 01/30/23 Due: 01/30/24

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01214993 Org: User:
Start: 10/31/10 End: 11/30/10 Due: 11/30/11

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01967771 Org: User:
Start: 10/31/13 End: 01/31/14 Due: 01/31/15

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01848340 Org: User:
Start: 05/31/13 End: 07/31/13 Due: 07/31/14